XOMA Royalty (XOMA) Stock Price, News & Analysis

Company Overview

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases. XOMA Royalty partners with biopharmaceutical companies across North America, Europe and other key markets, supporting the continued development and commercialization of innovative treatments. Its due-diligence process emphasizes assets with compelling clinical data, robust intellectual property protection and clear regulatory pathways.

Led by a management team with extensive experience in pharmaceutical finance, licensing and royalty management, XOMA Royalty leverages industry relationships to source and structure transactions. The board comprises executives and advisors with backgrounds in drug development, investment banking and asset management, positioning the company to identify high-quality royalty opportunities and steward its growing portfolio over time.

Key Stats

• Today's Range: $37.24 to $37.93
• 50-Day Range: $24.77 to $37.72
• 52-Week Range: $18.35 to $38.00
• Volume: 13,336 shs
• Average Volume: 44,956 shs
• Market Capitalization: $454.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.50
• Consensus Rating: Buy

XOMA Royalty Stock Analysis - MarketRank™

XOMA Royalty scored higher than 84% of companies evaluated by MarketBeat, and ranked 159th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

XOMA Royalty has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

XOMA Royalty has a consensus price target of $69.50, representing about 86.5% upside from its current price of $37.28.

Amount of Analyst Coverage

XOMA Royalty has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for XOMA Royalty are expected to grow in the coming year, from ($1.41) to ($0.55) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of XOMA Royalty is -24.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XOMA Royalty is -24.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XOMA Royalty has a P/B Ratio of 5.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of XOMA Royalty has been sold short.

Short Interest Ratio / Days to Cover

XOMA Royalty has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in XOMA Royalty has recently decreased by 10.92%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XOMA Royalty does not currently pay a dividend.

Dividend Growth

XOMA Royalty does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.0 / 5
• Environmental Score: -0.22

Percentage of Shares Shorted

2.41% of the float of XOMA Royalty has been sold short.

Short Interest Ratio / Days to Cover

XOMA Royalty has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in XOMA Royalty has recently decreased by 10.92%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 1.23

News Sentiment

XOMA Royalty has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for XOMA Royalty this week, compared to 3 articles on an average week.

MarketBeat Follows

2 people have added XOMA Royalty to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XOMA Royalty insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.20% of the stock of XOMA Royalty is held by insiders.

Percentage Held by Institutions

95.92% of the stock of XOMA Royalty is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XOMA Stock Analysis - Frequently Asked Questions

How have XOMA shares performed this year?

XOMA Royalty's stock was trading at $26.28 at the start of the year. Since then, XOMA shares have increased by 41.8% and is now trading at $37.2750.

How were XOMA Royalty's earnings last quarter?

XOMA Royalty Corporation (NASDAQ:XOMA) released its quarterly earnings results on Wednesday, August, 13th. The biotechnology company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.60. The biotechnology company earned $13.13 million during the quarter, compared to analysts' expectations of $9.39 million. XOMA Royalty had a positive trailing twelve-month return on equity of 2.63% and a negative net margin of 27.57%.

Who are XOMA Royalty's major shareholders?

XOMA Royalty's top institutional shareholders include BVF Inc. IL (21.64%), Opaleye Management Inc. (2.13%), Geode Capital Management LLC (1.70%) and Stonepine Capital Management LLC (1.27%). Insiders that own company stock include Bvf Partners L P/Il, Owen Hughes, Joseph M Limber and Bradley Sitko.
View institutional ownership trends.

How do I buy shares of XOMA Royalty?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of XOMA Royalty own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XOMA Royalty investors own include American Water Works (AWK), Waste Connections (WCN), AU Optronics (AUOTY), The RMR Group (RMR), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:XOMA
• CIK: 791908
• Web: www.xoma.com
• Phone: (510) 204-7200
• Fax: 510-649-7571
• Employees: 10
• Year Founded: 1981

Price Target and Rating

• Average Price Target for XOMA Royalty: $69.50
• High Price Target: $104.00
• Low Price Target: $35.00
• Potential Upside/Downside: +86.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$13.82 million
• Net Margins: -27.57%
• Pretax Margin: -34.07%
• Return on Equity: 2.63%
• Return on Assets: 0.97%

Debt

• Debt-to-Equity Ratio: 1.41
• Current Ratio: 4.88
• Quick Ratio: 4.88

Sales & Book Value

• Annual Sales: $28.49 million
• Price / Sales: 15.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.95 per share
• Price / Book: 5.36

Miscellaneous

• Outstanding Shares: 12,090,000
• Free Float: 11,218,000
• Market Cap: $450.41 million
• Optionable: Optionable
• Beta: 0.98